Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of multiple myeloma (ICD-9: 203.00; ICD-10: C90.0x, C90)
Are ≥18 years of age at the index date
Have received a lenalidomide-containing regimen and received a proteasome inhibitor; exposures do not need to occur within the same line of therapy
Have received ≥1 subsequent lines of therapy after lenalidomide and proteasome inhibitor exposure
Have received one of the following treatment regimens as the subsequent line (index line) after lenalidomide and proteasome inhibitor exposure:
* Pomalidomide-containing regimens:
Daratumumab, pomalidomide, and dexamethasone (DPd)
Carfilzomib, pomalidomide, and dexamethasone (KPd)
* Non-pomalidomide-containing regimens:
Daratumumab, lenalidomide, and dexamethasone (DRd; lenalidomide-refractory participants only)
Daratumumab, bortezomib, and dexamethasone (DVd)
Daratumumab, carfilzomib, and dexamethasone (DKd)
You may not be if
Have \<6 months of follow-up from the index date; participants who died will be included even with \<6 months follow-up, but participants who died within 1 month after the index date will be excluded
Have \<6 months pre-index enrollment
Have other primary cancer diagnoses within 1 year pre-index
